Hims & Hers Health, Inc.
$28.91
▼
-2.92%
2026-04-22 10:12:13
www.hims.com
NYQ: HIMS
Explore Hims & Hers Health, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.55 B
Current Price
$28.91
52W High / Low
$70.43 / $13.74
Stock P/E
56.32
Book Value
$2.38
Dividend Yield
—
ROCE
6.03%
ROE
25.23%
Face Value
—
EPS
$0.51
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,442
Beta
2.31
Debt / Equity
207.16
Current Ratio
1.9
Quick Ratio
1.7
Forward P/E
13.69
Price / Sales
1.89
Enterprise Value
$4.97 B
EV / EBITDA
28.3
EV / Revenue
2.12
Rating
Hold
Target Price
$24
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
Cons
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Phibro Animal Health Corporation | $56.51 | 24.91 | $2.29 B | 0.85% | 10.35% | 31.8% | $60.08 / $16.16 | $8.2 |
| 2. | Harrow, Inc. | $40.5 | — | $1.51 B | — | 10.06% | -8.47% | $54.85 / $21.12 | $1.41 |
| 3. | Neurocrine Biosciences, Inc. | $130.77 | 28.05 | $13.18 B | — | 16.37% | 16.38% | $160.18 / $98.95 | $32.5 |
| 4. | Citius Oncology, Inc. | $0.92 | — | $77.5 M | — | -45.72% | -47.41% | $6.19 / $0.49 | $0.69 |
| 5. | Indivior Pharmaceuticals, Inc. | $32.42 | 31.62 | $3.95 B | — | 92.33% | -96.33% | $38 / $8.69 | $-0.78 |
| 6. | BioAge Labs, Inc. | $18.8 | — | $820.58 M | — | -33.77% | -27.09% | $24 / $3.63 | $7.28 |
| 7. | Biofrontera Inc. | $1.09 | — | $12.81 M | — | -68.08% | -1.41% | $1.19 / $0.54 | $0.9 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 617.82 M | 598.98 M | 544.83 M | 586.01 M | 481.14 M |
| Operating Profit | 9.19 M | 11.81 M | 26.72 M | 57.9 M | 18.6 M |
| Net Profit | 20.6 M | 15.77 M | 42.51 M | 49.48 M | 26.02 M |
| EPS in Rs | 0.09 | 0.07 | 0.19 | 0.23 | 0.12 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.35 B | 1.48 B | 872 M | 526.92 M |
| Operating Profit | 105.61 M | 61.9 M | -29.45 M | -68.7 M |
| Net Profit | 128.37 M | 126.04 M | -23.55 M | -65.68 M |
| EPS in Rs | 0.58 | 0.57 | -0.11 | -0.3 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.15 B | 707.54 M | 441.19 M | 366.34 M |
| Total Liabilities | 1.61 B | 230.82 M | 97.16 M | 54.6 M |
| Equity | 540.93 M | 476.72 M | 344.03 M | 311.74 M |
| Current Assets | 767.64 M | 395.83 M | 265.05 M | 216.59 M |
| Current Liabilities | 404.43 M | 221.37 M | 88.47 M | 47.94 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 300.01 M | 251.08 M | 73.48 M | -26.53 M |
| Investing CF | -1.02 B | -19.05 M | -12.11 M | 34.7 M |
| Financing CF | 729.62 M | -107.84 M | -11.47 M | -33.13 M |
| Free CF | 57.41 M | 198.33 M | 46.99 M | -33.78 M |
| Capex | -242.59 M | -52.75 M | -26.49 M | -7.25 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 69.33% | 65.49% | — | — |
| Earnings Growth % | 635.28% | 64.15% | — | — |
| Profit Margin % | 8.54% | -2.7% | -12.46% | — |
| Operating Margin % | 4.19% | -3.38% | -13.04% | — |
| Gross Margin % | 79.45% | 81.99% | 77.57% | — |
| EBITDA Margin % | 5.35% | -2.29% | -11.62% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.